Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
New deal strengthens Congenica’s presence in India
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated